燃烧的多发性骨髓瘤:诊断和风险分层的进步,以及不断发展的治疗策略
1Department of Hematology, Japanese Red Cross Medical Center, 4-Chōme-1-22 Hiroo, Shibuya-Ku, Tokyo, 150-8935, Japan. taku_k_1123@mac.com.
International journal of hematology
|November 1, 2025
概括
燃烧多发性髓瘤 (SMM) 是症状多发性髓瘤 (MM) 的前体. 诊断和风险分层方面的进步改善了SMM管理,早期干预有希望,但需要仔细评估风险和益处.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 燃烧性多发性骨髓瘤 (SMM) 是症状性多发性骨髓瘤 (MM) 的前身阶段.
- 诊断标准的进步 (例如,SLiM-CRAB) 提高了SMM和MM之间的区别.
- 中小企业管理的多样性需要精细的风险分层和管理策略.
研究的目的:
- 审查最近在SMM的诊断,风险分层和管理方面的进展.
- 讨论SMM病原和治疗策略的不断变化的理解.
- 突出在SMM中需要个性化的治疗方法.
主要方法:
- 对当代诊断标准和风险分层模型的审查 (例如,Mayo 20/2/20).
- 对基因组和免疫学研究的分析,以确定疾病驱动因素和免疫失调.
- 对早期干预策略 (莱纳利多米德,达拉图穆马布) 和密集治疗方案 (GEM-CESAR,ASCENT) 的临床试验数据的评估.
主要成果:
- 改善了诊断准确度和SMM进展的风险预测.
- 识别SMM进化中的关键分子驱动因素和免疫模式.
- 临床试验表明,早期干预和密集治疗方案在延缓进展和实现最小残留疾病负面影响方面具有有效性.
结论:
- 目前的进展使SMM的更精确的管理,平衡进展风险与治疗毒性.
- 早期干预策略和密集治疗方案显示出潜力,但需要长期的结果评估.
- 未来的研究重点是针对高风险SMM的基于细胞和抗体的疗法正在进行中,强调个性化护理.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
7.2K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.1K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K